SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM Statement

10 Feb 2016 07:00

RNS Number : 5837O
Victrex PLC
10 February 2016
 
 

 

 

 

10 February 2016

Victrex plc

AGM and Q1 Interim Management Statement

'Soft Q1; expectation of a stronger H2 underpins full year'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its first quarter (Q1) Interim Management Statement ahead of its Annual General Meeting today.

Pleasingly, the overall performance in our industrial markets outside of Oil & Gas and Electronics was solid. Invibio also showed a small improvement compared to Q1 2015. Whilst Q1 2016 was softer compared to Q1 2015, this reflects the expected lower volumes in Consumer Electronics and Oil & Gas, where the prior period comparatives are tougher and a worsening environment in that market since our 2015 preliminary results.

At a revenue and volume level, Q1 Group revenue of £56.0m was 6% down on the prior year (Q1 2015: £59.8m), with Group sales volume of 860 tonnes being 11% down on the prior year (Q1 2015: 967 tonnes).

Based on the outlook for Oil & Gas and lower Consumer Electronics volumes, we expect this softness to continue through the first half year. Compared to previous guidance, volumes from the Consumer Electronics opportunity will now be much more weighted to the second half, to reflect product launch cycles. Extending existing business and capturing value-added business in our markets beyond 2016, including across the whole of Consumer Electronics, remains our focus.

David Hummel, Chief Executive of Victrex, said: "Whilst we expect the softness in Q1 to continue through the first half year, our latest view for the second half, including Consumer Electronics being much more weighted to the second half, points towards a stronger performance, compared to the second half of 2015.

"These assumptions mean we are comfortable with current expectations for the full year.

"Looking further ahead, our medium to longer term portfolio remains attractive, alongside our focused strategy of moving further downstream and an increasingly value-added proposition."

Victrex retains a strong financial position, with no significant changes since 30 September 2015.

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 7809 595831

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Teneo Strategy:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

 

 

 

Analyst and investor call:

A conference call for analysts and investors will be held this morning at 08.30am. Please contact Laura Stewart at Teneo Strategy for details on +44 (0) 203 603 5220 or laura.stewart@teneostrategy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMLLFETFVIAIIR
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.